Liver function tested for new cancer drug

NCT ID NCT07144111

Recruiting now Knowledge-focused Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 30 times

Summary

This study looks at how a single dose of the drug inavolisib is handled by the body in people with moderate or severe liver impairment compared to healthy volunteers. About 32 adults will take one dose and have their blood levels measured. The goal is to understand safety and dosing for future use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Orange County Research Center
RECRUITING

Lake Forest, California, 92630, United States
Orlando Clinical Research Center
RECRUITING

Orlando, Florida, 32809, United States
Pinnacle Clinical Research - San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
The Texas Liver Institute, Inc.
RECRUITING

San Antonio, Texas, 78215, United States

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC IMPAIRMENT